Product Description
KUR-101 is being developed by Kures for the treatment of acute pain. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05114265?term=KUR-101&draw=2&rank=1)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kures
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Acute Pain
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05114265 |
KUR-101-101 | P1 |
Completed |
Acute Pain |
2022-10-12 |
50% |
2022-12-15 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/23/2022 |
News Article |
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101 |
|
11/14/2022 |
News Article |
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates |
|
10/20/2022 |
News Article |
atai Life Sciences Announces R&D Day Agenda |
|
10/12/2022 |
News Article |
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD |